710 results match your criteria Expert opinion on emerging drugs[Journal]


Emerging PEGylated non-biologic drugs.

Expert Opin Emerg Drugs 2019 Apr 8. Epub 2019 Apr 8.

a College of Pharmacy, Chung-Ang University , Seoul 06974 , Republic of Korea.

Introduction: PEGylation is a well-established technology for improving the therapeutic value of drugs by attaching polyethylene glycol (PEG). The first PEGylated enzyme products appeared on the market in the early 1990s; currently, more than 18 PEGylated products have been approved by Food and Drug Administration, which encompass various classes of drug molecules, such as enzymes, interferons, granulocyte colony-stimulating factors, hormones, antibody fragments, coagulation factors, oligonucleotide aptamers, synthetic peptides, and small organic molecules. Areas covered: While PEGylated products mainly comprise biologic drugs, such as recombinant proteins and enzymes, non-biologic drugs have recently emerged as a target for PEGylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1604684DOI Listing
April 2019
1 Read

What role do pharmaceuticals play in the treatment of Peyronie's disease and is there a need for new emerging drugs?

Expert Opin Emerg Drugs 2019 03 19;24(1):1-4. Epub 2019 Mar 19.

a Department of Urology , University Hospitals Leuven , Leuven , Belgium.

Introduction: Finding novel medical treatment for Peyronie's disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways. Focusing on a single target during antifibrotic drug development has not led to the development of many efficacious drugs, especially in PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1591370DOI Listing

Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation.

Expert Opin Emerg Drugs 2019 03 18;24(1):55-61. Epub 2019 Mar 18.

a Institute of Applied Health Research , University of Birmingham , Birmingham , UK.

Introduction: Thromboembolic diseases are leading cause of mortality accounting for an estimated 1 in 4 deaths all over the world. Anticoagulation remains the mainstay of prevention and treatment of venous thromboembolic disorders. Conventional anticoagulants have been efficiently used over the last decades, but their clinical use encounters safety and convenience issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1591368DOI Listing
March 2019
5 Reads

Emerging drugs for treating the acute respiratory distress syndrome.

Expert Opin Emerg Drugs 2019 03 18;24(1):29-41. Epub 2019 Mar 18.

a Wellcome-Wolfson Institute for Experimental Medicine , Queen's University Belfast , Belfast , UK.

Introduction: The acute respiratory distress syndrome (ARDS) is a common and catastrophic condition, with a high mortality rate and economic burden on society. Despite 50 years of study, there is no specific pharmacological therapy for ARDS. Areas covered: This review outlines the definitions, epidemiology, risk factors and pathophysiology of ARDS. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2019.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2019.1591369DOI Listing
March 2019
3 Reads

Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective.

Expert Opin Emerg Drugs 2019 03;24(1):43-53

d Pediatric Oncology Unit , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.

Introduction: in this review we discuss the standard of care for both pediatric and adult synovial sarcoma (SS), the prognostic differences between them, and the treatments available for localized and advanced diseases. We also overview the biology and the recent drugs under consideration in clinical trials on SS. Areas covered: we focus on new targeted therapies being investigated for advanced SS, especially anti-angiogenic drugs, and immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1591367DOI Listing
March 2019
1 Read
3.058 Impact Factor

Emerging drugs for the treatment of clostridium difficile.

Expert Opin Emerg Drugs 2019 03 20;24(1):17-28. Epub 2019 Mar 20.

a UOC di Medicina Interna , F. Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore , Roma , Italy.

Introduction: Clostridium difficile or Clostridioides difficile (C. difficile) infection represents the most common cause of healthcare-associated infection. Over the last decades, the incidence and severity of C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1591371DOI Listing
March 2019
10 Reads

Emerging drugs for the treatment of hypercholesterolemia.

Expert Opin Emerg Drugs 2019 03 21;24(1):63-69. Epub 2019 Mar 21.

a Medical and Surgical Sciences Department , University of Bologna , Bologna , Italy.

Introduction: Despite the consolidated role of statins and ezetimibe to treat hypercholesterolemia, often the desirable low-density lipoprotein cholesterol (LDL-C) values are not achieved, with a consequent increase of the residual cardiovascular (CV) risk. Areas covered: In this review, we summarize the main pharmacological characteristics of new lipid-lowering drugs, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, cholesteryl ester transfer protein inhibitors, microsomal triglyceride transfer protein inhibitors, ATP citrate lyase inhibitors, antisense oligonucleotides, small interfering RNA, and peroxisome proliferator-activated receptors type α agonists. The available clinical evidence of efficacy and safety as well as the prospects of application, based on the different mechanisms and targets of action, is critically discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1591372DOI Listing
March 2019
1 Read

Emerging drugs for EGFR-mutated non-small cell lung cancer.

Expert Opin Emerg Drugs 2019 03 20;24(1):5-16. Epub 2018 Dec 20.

a Department of Oncology , Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , NY , USA.

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, these agents are associated with inevitable treatment resistance. Newer generations of TKIs are under development that may prevent or overcome resistance and enhance intracranial activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1558203DOI Listing
March 2019
2 Reads

An update: emerging drugs for tinnitus.

Expert Opin Emerg Drugs 2018 Dec 7:1-10. Epub 2018 Dec 7.

c Department of Psychiatry and Psychotherapy , University of Regensburg , Regensburg , Germany.

Introduction: During the last decade, a number of candidate drugs for the treatment of tinnitus have emerged with the hope of alleviating the burden of millions of sufferers with a persisting ringing in their ears. Knowledge of the pathophysiologic mechanisms has progressed remarkably in the recent years, which has led to the identification of potential new drug targets for the treatment of tinnitus. However, pharmacologic interventions are still limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1555240DOI Listing
December 2018
2 Reads

Novel therapeutic approaches in primary hyperoxaluria.

Expert Opin Emerg Drugs 2018 Dec 12:1-9. Epub 2018 Dec 12.

a Division of Pediatric Nephrology , University Childrens Hospital, Universitatsklinikum Bonn , Bonn , Germany.

Introduction: Currently, three types of primary hyperoxaluria (PH I-III) are known, all based on different gene-mutations affecting the glyoxylate metabolism in the liver. Disease hallmark is an increased endogenous oxalate production and thus massively elevated urinary excretion of oxalate and other type-specific metabolites. Hyperoxaluria induces the formation of calcium-oxalate kidney stones and/or nephrocalcinosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1552940DOI Listing
December 2018
8 Reads

An update on emerging drugs for the treatment of erectile dysfunction.

Expert Opin Emerg Drugs 2018 Dec 3. Epub 2018 Dec 3.

a Department of Urology , University Hospitals Leuven , Belgium.

Introduction: Erectile dysfunction is an extremely frequent and extensively studied condition, currently affecting the lives of tens of millions of men around the globe. The extensive knowledge of its pathophysiology has led to the development of phosphodiesterase 5-inhibitors, which can facilitate sexual intercourse in a large number of patients. However, an ever-increasing number of patients is unresponsive to these drugs due to underlying comorbidities or previous surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1552938DOI Listing
December 2018
2 Reads

Emerging drugs for migraine treatment: an update.

Expert Opin Emerg Drugs 2018 Nov 28. Epub 2018 Nov 28.

c Department of Clinical and Molecular Medicine , Sapienza" University, "Sant'Andrea" Hospital, Regional Referral Headache Centre , Rome , Italy.

Introduction: Migraine is a very frequent and disabling neurological disorder. The current treatment options are old, generally poorly tolerated and not migraine-specific, reflecting the low priority of migraine research and highlighting the vast unmet need in its management. Areas covered: Advancement in the understanding of migraine pathophysiological mechanisms and identification of novel potentially meaningful targets have resulted in a multitude of emerging acute and preventive treatments. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1552939DOI Listing
November 2018
8 Reads

Emerging drugs for the treatment of Dravet syndrome.

Expert Opin Emerg Drugs 2018 Nov 27. Epub 2018 Nov 27.

d Neurology Unit, S. Anna Hospital , Como , Italy.

Introduction: Dravet syndrome (DS) is an early-onset genetic developmental epileptic encephalopathy characterized by multiple seizure types which are refractory to antiseizure medication. There is an unmet need for effective and tolerable drugs to control different seizure types in DS types, with the aim of improving quality of life and preventing neurological impairment. Areas covered: Narrative review of efficacy and tolerability of fenfluramine, cannabidiol (CBD), verapamil and modulators of serotonin signaling pathways (lorcaserin or trazodone) in the treatment of DS. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1552937DOI Listing
November 2018
15 Reads

Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.

Expert Opin Emerg Drugs 2018 12 28;23(4):271-282. Epub 2018 Nov 28.

a Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry , Western University and London Health Sciences Centre , London , ON , Canada.

Introduction: Disease progression despite androgen suppression defines lethal castration-resistant prostate cancer (CRPC). Most of these cancers remain androgen receptor (AR)-signaling dependent. Therapy for metastatic CRPC includes abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, sipuleucel-T, and radium-223. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1547707DOI Listing
December 2018
18 Reads

Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.

Expert Opin Emerg Drugs 2018 12 3;23(4):331-347. Epub 2018 Dec 3.

a Rheumatology Department, Royal North Shore Hospital, and, Institute of Bone and Joint Research, Kolling Institute , University of Sydney , Sydney , Australia.

Introduction: Osteoarthritis (OA) is a leading cause of pain and disability among adults with a current prevalence of around 15% and a predicted prevalence of 35% in 2030 for symptomatic OA. It is increasingly recognized as a heterogeneous multi-faceted joint disease with multi-tissue involvement of varying severity. Current therapeutic regimens for OA are only partially effective and often have significant associated toxicities. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1547706DOI Listing
December 2018
304 Reads
3.058 Impact Factor

An update: emerging drugs to treat squamous cell carcinomas of the head and neck.

Expert Opin Emerg Drugs 2018 Oct 30:1-17. Epub 2018 Oct 30.

a Department of Otolaryngology-Head and Neck Surgery , University of California , San Francisco , CA , USA.

Introduction: Subsequent to the 2006 FDA approval of cetuximab, a variety of molecular targeting agents have been evaluated in head and neck squamous cell carcinoma (HNSCC). The treatment outcomes of recurrent and/or metastatic (R/M) HNSCC, in particular, remain dismal. The 2016 FDA approval of PD-1 immune checkpoint inhibitors has expanded the treatment options for R/M HNSCC and highlights the potential for immune-based therapies. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1543400DOI Listing
October 2018
10 Reads

Emerging drugs for focal epilepsy.

Authors:
Marco Mula

Expert Opin Emerg Drugs 2018 09 27;23(3):243-249. Epub 2018 Sep 27.

a Institute of Medical and Biomedical Education , St George's University of London , London , UK.

Introduction: Epilepsy is one of the most serious neurological conditions, affecting almost 50 million people around the world. Despite more than 20 antiepileptic drugs (AEDs) available, seizures are still uncontrolled in one third of patients. Areas covered: The present paper reviews current compounds in preclinical and clinical development for the treatment of focal epilepsies and new potential molecular targets recently identified. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1527903DOI Listing
September 2018
19 Reads

Expert opinion on existing and developing drugs to treat female sexual dysfunction.

Expert Opin Emerg Drugs 2018 09 11;23(3):223-230. Epub 2018 Oct 11.

a University of Virginia , Charlottesville , VA , USA.

Introduction: Female sexual dysfunction (FSD) is a highly prevalent, yet commonly underdiagnosed and undertreated condition. This paper reviews the diagnostic terminology for FSD, and basic sexual physiology in women. The Food and Drug Administration (FDA) approved drugs for FSD are discussed, followed by investigational drugs for FSD currently in phase 2 or 3 clinical trials, reasons for failure of drug development, and potential future drug targets. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1527901DOI Listing
September 2018
14 Reads

Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.

Expert Opin Emerg Drugs 2018 09 15;23(3):231-241. Epub 2018 Oct 15.

a Division of Medical Oncology , 'S. G. Moscati' Hospital , Avellino , Italy.

Introduction: The medical treatment of non-small cell lung cancer (NSCLC) has radically changed over the last 10 years thanks to new molecular-targeted drugs able to act on biological mechanisms involved in tumor development. One such mechanism is the aberrant anaplastic lymphoma kinase (ALK) activation: patients with ALK-driven NSCLC benefit from treatments that selectively inhibit its pathogenetic mechanism. Areas covered: The first-generation ALK inhibitor is crizotinib, initially used in Europe as second-line treatment for ALK-positive metastatic NSCLC patients, then approved as the standard first-line (already approved in the USA as front-line therapy). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1527902DOI Listing
September 2018
4 Reads

Emerging PARP inhibitors for treating breast cancer.

Expert Opin Emerg Drugs 2018 09 29;23(3):211-221. Epub 2018 Sep 29.

a René Gauducheau , Institut de Cancérologie de l'Ouest , St Herblain , France.

Introduction: Some breast cancers harbor defects in DNA repair pathways, including BRCA1 and BRCA2 mutations, leading to a genomic instability. Compromised DNA-damage repair response is found in 11 to 42% of triple negative breast cancers, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1527900DOI Listing
September 2018
2 Reads

Expert opinion on emerging urate-lowering therapies.

Expert Opin Emerg Drugs 2018 09;23(3):201-209

c Medicine Service , VA Medical Center , Birmingham , AL , USA.

Introduction: There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate (levotofisopam, ulodesine, verinurad, merbarone, KUX-1151, UR-1102, FYU-981, SEL-212), or treating gout flares (canakinumab, bucillamine) or both (arhalofenate, diacerein). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1527899DOI Listing
September 2018
3 Reads

Emerging antibacterial and antiviral drugs for treating respiratory tract infections.

Expert Opin Emerg Drugs 2018 09 30;23(3):185-199. Epub 2018 Jul 30.

a Department of Pathophysiology and Transplantation , Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center,IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico , Milan , Italy.

Introduction: Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1504020DOI Listing
September 2018
14 Reads

Emerging drugs for eosinophilic esophagitis.

Expert Opin Emerg Drugs 2018 06 8;23(2):173-183. Epub 2018 Jun 8.

b Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital of Illinois , University of Illinois College of Medicine , Peoria , IL , United States.

Introduction: Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1483335DOI Listing
June 2018
19 Reads

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.

Expert Opin Emerg Drugs 2018 06 6;23(2):111-122. Epub 2018 Jun 6.

b Department of Medicine , Division of Hematology Oncology , United States.

Introduction: The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1479396DOI Listing
June 2018
7 Reads

Emerging reverse transcriptase inhibitors for HIV-1 infection.

Expert Opin Emerg Drugs 2018 06 10;23(2):149-157. Epub 2018 May 10.

a Department of Internal Medicine , University of Cincinnati Medical Center , Cincinnati , OH , USA.

Introduction: There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1474202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158299PMC
June 2018
5 Reads

Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.

Expert Opin Emerg Drugs 2018 06 16;23(2):135-147. Epub 2018 May 16.

a Department of Urology , Academic Medical Center , Amsterdam , The Netherlands.

Introduction: Bladder cancer (BC) is a severe health burden: and has high recurrence and progression rates. Standard treatment starts with TURB followed by intravesical chemotherapy with Mitomycin C or immunotherapy with BCG. However, successful management still remains a challenge, because approximately 30% of patients have recurrence or progression within 5 years, and treatment has considerable side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1474201DOI Listing
June 2018
3 Reads

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.

Expert Opin Emerg Drugs 2018 06 8;23(2):159-172. Epub 2018 May 8.

a Inova Advanced Lung Disease and Lung Transplant program , Falls Church , VA , USA.

Introduction: Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic lung disease of unknown etiology associated with a high morbidity and mortality. The hallmark of the disease is impaired healing after alveolar epithelial injury in the setting of a genetic predisposition. Development of two new drugs has changed the landscape of the treatment of IPF but more work is needed to improve outcomes and improve survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1471465DOI Listing
June 2018
4 Reads

Emerging drugs for primary progressive multiple sclerosis.

Expert Opin Emerg Drugs 2018 06 24;23(2):97-110. Epub 2018 Apr 24.

a Department of Neurology and Neurotherapeutics , University of Texas Southwestern Medical Center , Dallas , TX , USA.

Introduction: The identification of effective therapies for progressive forms of multiple sclerosis (MS) has remains a priority and challenge for the global MS community. Despite a few proposed mechanisms, a more complete understanding of the mechanisms involved in the pathogenesis of these MS phenotypes, animal models that incorporate these pathogenic characteristics, novel trial designs, drug repurposing strategies, and new models of collaboration between clinical and basic science personnel may be required in identifying effective therapies. Areas covered: Here, we review the current knowledge on putative pathogenic mechanisms in primary progressive MS (PPMS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1463370DOI Listing
June 2018
5 Reads

PARP inhibitors for homologous recombination-deficient prostate cancer.

Expert Opin Emerg Drugs 2018 06 4;23(2):123-133. Epub 2018 Apr 4.

a Oncology and Urology , Johns Hopkins Sidney Kimmel Cancer Center , Baltimore , MD , USA.

Introduction: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant disease. This discovery has yielded novel therapeutic opportunities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1459563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088797PMC
June 2018
6 Reads

Emerging growth factor receptor antagonists for ovarian cancer treatment.

Expert Opin Emerg Drugs 2018 03 12;23(1):1-16. Epub 2018 Mar 12.

a Princess Margaret Cancer Centre , Toronto , Canada.

Introduction: Epithelial Ovarian Cancer (EOC) is the most lethal gynecological malignancy. EOC outcomes remain unsatisfactory despite aggressive surgical approach, disease chemo-sensitivity and recent introduction of agents targeting angiogenesis and tumour genome instability. Advances in EOC research have allowed for a tailored treatment approach and accelerated development of novel treatments strategies from bench to bed side, anticipated to improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1446942DOI Listing
March 2018
4 Reads

Emerging pharmacotherapies for the treatment of atrial fibrillation.

Expert Opin Emerg Drugs 2018 03 13;23(1):25-36. Epub 2018 Mar 13.

a Department of Scienze Cardiovascolari , Clinica di Cardiologia Universita' Politecnica delle Marche - Scienze Cardiovascolari , Ancona , Italy.

Introduction: The main aim of current research on the field of atrial fibrillation (AF) treatment is to find new antiarrhythmic drugs with less side effects. Areas covered: Dronedarone and vernakalant showed promising result in term of efficacy and safety in selected patients. Ranolazine and colchicine are obtaining a role as a potential antiarrhythmic drug. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1446941DOI Listing
March 2018
6 Reads

Emerging treatment options for uterine fibroids.

Expert Opin Emerg Drugs 2018 03 12;23(1):17-23. Epub 2018 Mar 12.

d Gynecology Department , Cliniques Universitaires St-Luc , Brussels , Belgium.

Introduction: Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1446943DOI Listing
March 2018
10 Reads

Emerging drugs for the treatment of Myelofibrosis.

Expert Opin Emerg Drugs 2018 03 6;23(1):37-49. Epub 2018 Mar 6.

a Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute , New York , NY , USA.

Introduction: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia vera myelofibrosis and post essential thrombocythemia myelofibrosis. MF is a life-threatening hematologic malignancy characterized by dysregulation of the Janus associated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling network and a heightened inflammatory state. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1445718DOI Listing
March 2018
27 Reads

Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia.

Expert Opin Emerg Drugs 2018 03 3;23(1):51-62. Epub 2018 Mar 3.

a Princess Margaret Cancer Centre , University Health Network , Toronto , ON , Canada.

Introduction: BCR-ABL-directed tyrosine kinase inhibitors (TKIs) have revolutionised therapy for chronic myeloid leukemia. However, despite the availability and efficacy of this class of agents, lifelong treatment is still required in a significant proportion of patients Areas covered: We give an overview of the currently available BCR-ABL-directed TKIs and other conventional therapies for CML. We proceed to review the current market and some of the scientific rationale for new drug development before outlining a number of novel therapies, considered broadly as immunotherapies and targeted agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1445717DOI Listing
March 2018
5 Reads

Emerging drugs for the treatment of axial spondyloarthritis.

Expert Opin Emerg Drugs 2018 03 1;23(1):83-96. Epub 2018 Mar 1.

a Department of Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin , Berlin , Germany.

Introduction: The treatment of axial spondyloarthritis(axSpA) has been for nearly 15 years constricted to non-steroidal antirheumatic drugs and TNFα inhibitors. With the approval of secukinumab, a drug targeting the interleukin(IL)-17 axis became available. Nonetheless, an unmet need for further emerging therapeutic options remains. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1445719DOI Listing
March 2018
10 Reads

Emerging molecular target antagonists for the treatment of biliary tract cancer.

Expert Opin Emerg Drugs 2018 03 28;23(1):63-75. Epub 2018 Feb 28.

a Department of Oncology , University of Turin Medical School , Turin , Italy.

Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1444749DOI Listing
March 2018
20 Reads

Emerging drugs for alopecia areata: JAK inhibitors.

Expert Opin Emerg Drugs 2018 03 26;23(1):77-81. Epub 2018 Feb 26.

b Fredric Brandt Endowed Professor of Dermatology - Miller School of Medicine , University of Miami , Miami , FL , USA.

Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1444750DOI Listing
March 2018
4 Reads

An update on new and emerging therapies for cystic fibrosis.

Expert Opin Emerg Drugs 2017 12 22;22(4):331-346. Epub 2017 Dec 22.

c Division of Pulmonary Medicine, Department of Pediatrics , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.

Introduction: Cystic fibrosis (CF) is a genetic disorder that results in a multi-organ disease with progressive respiratory decline that ultimately leads to premature death. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR anion channel. Established CF treatments target downstream manifestations of the primary genetic defect, including pulmonary and nutritional interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1418324DOI Listing
December 2017
11 Reads

An update on emerging drugs for fibromyalgia treatment.

Expert Opin Emerg Drugs 2017 12 19;22(4):357-367. Epub 2017 Dec 19.

b Department of Rheumatology , ASST Fatebenefratelli-Sacco , Milan , Italy.

Introduction: Fibromyalgia (FM) is a chronic disorder whose symptoms of pain, fatigue, sleep disturbances and depression have a devastating effect on patients' lives as it limits their ability to engage in everyday working and social activities, and make it difficult to maintain normal relationships with family, friends and employers. None of the currently available drugs are fully effective against the whole spectrum of symptoms. The aim of this narrative review is to summarise the data relating to the new therapeutic options that have become available over the last few years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1418323DOI Listing
December 2017
14 Reads

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Expert Opin Emerg Drugs 2017 12 19;22(4):347-355. Epub 2017 Dec 19.

b Dana Farber Cancer Institute , Boston , MA , USA.

Introduction: The treatment of urothelial carcinoma (UC) had remained unchanged for several years until the recent FDA approval of immune checkpoint inhibitors (CPIs) in the salvage setting. Novel dual CPI-CPI and CPI-chemotherapy combinations are now being investigated aggressively as first line therapy for metastatic disease. Areas covered: We discuss the recent insights into the tumor biology of UC, which may impact the prognosis as well as assist in developing precision medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1416092DOI Listing
December 2017
11 Reads

Emerging drugs for the treatment of gastrointestinal stromal tumour.

Expert Opin Emerg Drugs 2017 12 18;22(4):317-329. Epub 2017 Dec 18.

b Director of Sarcoma Oncology, Associate Director for Clinical Research , Fox Chase Cancer Center , Philadelphia , PA , USA.

Introduction: Tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape for patients with gastrointestinal stromal tumors (GIST). Unfortunately, resistance to the currently approved TKIs poses a huge challenge, and patients are in need of additional therapeutic options. Fortunately, many novel therapeutic approaches are being tested in treatment of GIST to overcome resistance to the approved TKIs Areas covered: We performed an extensive literature (PUBMED) search to identify emerging drugs being tested in treatment of GIST in early phase clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1411479DOI Listing
December 2017
5 Reads

Medications for substance use disorders (SUD): emerging approaches.

Expert Opin Emerg Drugs 2017 12 30;22(4):301-315. Epub 2017 Oct 30.

a Laboratory in the Biology of Addictive Diseases , The Rockefeller University , New York , NY , USA.

Introduction: Substance use disorders are a group of chronic relapsing disorders of the brain, which have massive public health and societal impact. In some disorders (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1395855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276123PMC
December 2017
4 Reads

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

Expert Opin Emerg Drugs 2017 09 3;22(3):285-299. Epub 2017 Sep 3.

a Baylor College of Medicine , Section of Pulmonary and Critical Care Medicine , Houston , TX , USA.

Introduction: Chronic obstructive pulmonary disease (COPD), characterized by persistent and partially reversible airflow obstruction, is a leading cause of morbidity and mortality worldwide. Long-acting inhaled bronchodilators form the backbone for the maintenance therapy for this disease. The ultra-long-acting β-agonists (ultra-LABAs) represent novel pharmacologic agents with interesting potential benefits as stand-alone therapy or in combination with other therapies for the treatment of COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1367382DOI Listing
September 2017
44 Reads

An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.

Expert Opin Emerg Drugs 2017 09;22(3):213-222

a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.

Introduction: Mitosis is necessary to sustain life and is followed immediately by cell division into two daughter cells. Microtubules play a key role in the formation of the mitotic spindle apparatus and cytokinesis at the end of mitosis. Various anti-microtubule agents such as taxanes and vinca alkaloids are widely used in the treatment of advanced non-small cell lung cancer (NSCLC) but their use is associated with hematologic toxicity profile, acquired resistance and hypersensitivity reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1369952DOI Listing
September 2017
11 Reads

Emerging interleukin receptor antagonists for the treatment of asthma.

Expert Opin Emerg Drugs 2017 09 23;22(3):275-283. Epub 2017 Aug 23.

a Faculty of Medicine, Division of Respirology , University of British Columbia , Vancouver , BC , Canada.

Introduction: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. Most patients with asthma can be well-controlled with inhaled corticosteroids and, if necessary, the addition of a long-acting beta agonist. Despite these therapies, 5% to 10% of patients with asthma have severe, uncontrolled asthma. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2017.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2017.1369954DOI Listing
September 2017
56 Reads

Emerging drugs for the treatment of benign prostatic hyperplasia.

Expert Opin Emerg Drugs 2017 09 30;22(3):201-212. Epub 2017 Aug 30.

a Department of Urology , Weill Cornell Medicine-New York Presbyterian , New York , NY , USA.

Introduction: Benign prostatic hyperplasia (BPH) is a common condition affecting over 50% of men as they reach their 5 decade of life. This leads to a number of sequelae such as lower urinary tract symptoms, urinary retention and a decrease in quality of life. Currently, the available treatments for BPH are alpha blockers and 5-alpha reductase inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1369953DOI Listing
September 2017
69 Reads

Emerging antibody-drug conjugates for treating lymphoid malignancies.

Expert Opin Emerg Drugs 2017 09 28;22(3):259-273. Epub 2017 Aug 28.

a Department of Hematology , Medical University of Lodz , Lodz , Poland.

Introduction: Antibody-drug conjugates (ADC) are monoclonal antibodies (Mabs) attached to biologically active drugs through specialized chemical linkers. They deliver and release cytotoxic agents at the tumor site, reducing the likelihood of systemic exposure and therefore toxicity. These agents should improve the potency of chemotherapy by increasing the accumulation of cytotoxic the drug within or near the neoplastic cells with reduced systemic effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1366447DOI Listing
September 2017
10 Reads

New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.

Expert Opin Emerg Drugs 2017 09 3;22(3):223-233. Epub 2017 Sep 3.

a Department of Hematology and Oncology , Tufts University School of Medicine , Boston , MA , USA.

Introduction: Pancreatic adenocarcinoma is a devastating malignancy with an extremely poor prognosis. These tumors progress rapidly and somewhat silently with few specific symptoms and are relatively resistant to chemotherapeutic agents. Many agents, including cell cycle inhibitors, are under development for the treatment of this cancer for which there are disappointingly few treatment options. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2017.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2017.1362388DOI Listing
September 2017
17 Reads

Emerging anabolic agents in the treatment of osteoporosis.

Expert Opin Emerg Drugs 2017 09 4;22(3):247-257. Epub 2017 Aug 4.

b New Mexico Clinical Research & Osteoporosis Center , Albuquerque , NM , USA.

Introduction: Osteoporosis is a common skeletal disease with serious consequences due to osteoporotic fractures and high costs to society for post-fracture care. Most patients at high risk for fracture are not receiving care to reduce fracture risk. The osteoporosis treatment gap has reached crisis proportions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1362389DOI Listing
September 2017
13 Reads

Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.

Expert Opin Emerg Drugs 2017 09 4;22(3):235-246. Epub 2017 Aug 4.

a Department of Ophthalmology , Indiana University School of Medicine , Indianapolis , IN , USA.

Introduction: Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies. Areas covered: Brolucizumab and abicipar pegol have smaller molecular size, facilitating higher concentrations and potentially longer duration than current anti-VEGF agents. Agents being combined with anti-VEGFs include OPT-302 (to inhibit VEGF-C and VEGF-D); pegpleranib and rinucumab (to inhibit platelet derived growth factor, PDGF - but both failed to show consistently improved visual outcomes compared to anti-VEGF monotherapy); and RG7716, ARP-1536 and nesvacumab (to activate the Tie-2 tyrosine kinase receptor, which reduces permeability). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1362390DOI Listing
September 2017
12 Reads
3.060 Impact Factor